Ten Years … Gone “Hog Wild”

This started with the top trailing 10-year performers from the S&P 500, which is cool — and at least they got that going for them. But we know the virtues of All-of-the-Above investing, which means the Value Line 1700 list is even cooler. Look what Groundhog Nation did with them.

Carl Quintanilla (CNBC) provided this list of the best performing stocks in the S&P 500 since the market low ten years ago.

It’s been fun and rewarding for many. Take note how many of these have been covered and/or resident in our model portfolios, etc. since then.

Who did we miss? Why?

Spy top 50 performers since 2009 20190308

So what were you doing when the “Great” Recession bottomed on March 9, 2009? CNBC got this whole this started with the S&P 500 but we know that even better opportunity manifests in the Value Line 1700 — and we weren’t disappointed.

There are 1200 stocks with stock price data for 3/9/2009 and 3/8/2019, ten years later. Investing $100 into each of these 1200 ($120,000) would worth $1,012,892 this past weekend — an annualized total return of 23.8%. Sorry, Carl Quintanilla, but the S&P 500 checks in at 17.3%.

  • The annualized total return (10 years) on the Wilshire 5000 (VTSMX) is 17.5%. 655 of the 1200 stocks (54.6%) beat the market. This collective of gainers have an average quality ranking of 69.
  • 1138-of-1200 (94.8%) gained and a have a current value greater than $100. The stocks that lost ground have an average quality ranking of 27.
  • The top performing decile has a sales growth forecast of 9.2%. The bottom decile stands with a 5.3% growth forecast.
  • If the Value Line Arithmetic Average were “investable,” the annualized total return was 19.7% as 999.30 advanced to 6046.07 during the time period. All-of-the-Above Investing works.

Gone Hog Wild (March 2009)

Every year we run a stock picking contest that starts on Groundhog Day and continues until the next Groundhog Day. Back in March 2009, we featured the most-frequently selected stocks as something of a screening exercise. As the accompanying image shows, yes, Virginia, the average return forecast was “north” of 20% at the time.

The Sweet 16 stocks featured back in March 2009 generated a return of 21.2%.

The top performer was the swing-for-the-fences selection of Sigma Designs (SIGM) and every once in a while, Casey does not always strike out. 36.6% can be a wonderful thing. But the rest of the field was also formidable and include a number of community favorites (Manifest Investing 40 residents).

Sweet 16 (3/1/2009) Results — Ten Years Later. As shown the collective performance of the (16) selections known as “Heavy Hogs” delivered a 21.2% annualized total return. Dividends are included. We can’t help but note the strong performance from the companies at the top of the 10-year-old screening results vs. the achievements of some nearer the bottom. Quality Systems (QSII) morphed into NextGen Healthcare (NXGN). [Editor’s Note: If we’d only listened to Cy Lynch and WellCare Health Plans (WCG) at the time, +44.1%.] Buffalo Wild Wings (BWLD) was acquired by Arby’s after a considerable gain. Navellier Fundamental (NFMAX) evolved into a private wrap offering, results shown are from Navellier fact sheet (https://navellier.com/files/3815/4964/8534/fundamental-a-factsheet.pdf).


Invest With Your Friends.  The journey can be a most informative, rewarding and entertaining adventure.


Start a test drive (trial subscription) at http://www.manifestinvesting.com ($79/year, group discounts for club partners and educators) and participate in the next ten years of going “Hog Wild.”


Contact Mark Robertson via markr@manifestinvesting.com or via Twitter by reaching out to @manifestinvest.  Manifest Investing also maintains a “slipstream blog” at Facebook: https://www.facebook.com/manifestinvesting/  Comments and inquiries welcome.


The NEW CVS Health (CVS)

This article is a current example of the type of company analysis Manifest Investing (and our friends) performs on stocks following the time-honored (since 1941) methods of the modern investment club movement.  CVS is the 10th most widely-followed stock by our community of investors and is the 2nd most frequently-selected stock during our monthly FREE webcasts known as our Investing Round Table.  Note: The 9-year annualized rate of return for the stocks featured is 15.5%.  Start a test drive (trial subscription) at http://www.manifestinvesting.com ($79/year, group discounts for club partners and educators) and see the answers to some natural “next” questions including: (1) What about store growth? and (2) How much did Warren Buffett overpay for Heinz and did CVS pay too much for Aetna?

At CVS Health, we share a clear purpose: helping people on their path to better health. Through our health services, plans and community pharmacists, we’re pioneering a bold new approach to total health. Making quality care more affordable, accessible, simple and seamless, to not only help people get well, but help them stay well in body, mind and spirit.

Cy Lynch warned all of us as he selected CVS Health (CVS) again for the February Round Table. CVS now ranks as the 2nd most frequently selected company for the tracking portfolio. Cy’s warnings? (1) You can’t lean on the rear view mirror for this one. The historical data doesn’t include Aetna. (2) The fear and herd-following among the Rhinos has delivered some painful price action. [Note: The Rhinos just could be right.] (3) CVS is undergoing a high risk (general perception) transformation from the current business model to one that seeks to optimize wellness, decrease dependency on pharmaceutical band-aids (!!!) and fight to establish an effective go-to solution that serves customers with a cost effective path to health.

The Wind Is Blowing

Reference: Looking Ahead: 2019 Health Care Trends

Business Model Analysis (Sales)

CVS Health. Pro Forma Sales Projections. As Cy suggested, the company has shifted. The step change in sales due to the addition of Aetna can be seen in 2018. The growth rate (slope of the trend line) from 2010-2017 is visually different from the slope seen for 2018-2023. The former trend (10-12%) no longer applies to a stock study of the new CVS. It’s supporting information for what may be possible — but the growth rate suggested in the SEC filings is 6-7%. (Value Line has a much more pessimistic outlook for the 3-5 year forecast — resulting in a growth forecast of 4.5%)

The profitability forecast (according to CVS and the legions of Rhinos who chimed and rhymed with opinions about the Aetna deal) is available here also. Dividing the net income in 2022 into the the sales forecast, we see (11.6/333.4) = 0.035 = 3.5%

… And Now, The Rest Of The Story

My personal opinion is that it boils down to remembering and realizing that CVS is the company that discontinued the sale of cigarettes a few years ago to a chorus of whining and Armageddon commentary from the Rhinos.

This is massively challenging but a mission with merit. This core holding — at least temporarily — has shifted from blue chip stalwart to execution-based speculation. But it’s a good speculation based on the promises delivered by excellent management over the past several years. The investing jungle is full of doubting Rhinos and the stock price has been mightily challenged, accordingly. That said, the expectations (4% growth, 3.5% profitability, 11.5x average P/E) are the types of low bars that investors like Graham and Buffett have vision cast as stepping over them while others assail the assortment of 7-foot high jump bars with other opportunities.

Imagine them ripping out the chips and candy and recapturing the space with cost-effective access to doctors, physician’s assistants, nurse practitioners and various flavors of therapists and nutritional campaigns. Imagine America taking a few less pills and feeling comprehensively better. CVS ripped out the smoking products. How challenging is it to believe that they just might be serious about the rest of this?



Contact Mark Robertson via markr@manifestinvesting.com or via Twitter by reaching out to @manifestinvest.  Manifest Investing also maintains a “slipstream blog” at Facebook: https://www.facebook.com/manifestinvesting/  Comments and inquiries welcome.